US5719147A
(en)
*
|
1992-06-29 |
1998-02-17 |
Merck & Co., Inc. |
Morpholine and thiomorpholine tachykinin receptor antagonists
|
SG52217A1
(en)
*
|
1993-12-29 |
1998-09-28 |
Merck Sharp & Dohme |
Substituted morpholine derivatives and their use as therapeutic agents
|
IL112778A0
(en)
*
|
1994-03-04 |
1995-05-26 |
Merck & Co Inc |
Substituted heterocycles, their preparation and pharmaceutical compositions containing them
|
US5747491A
(en)
*
|
1994-05-05 |
1998-05-05 |
Merck Sharp & Dohme Ltd. |
Morpholine derivatives and their use as antagonists of tachikinins
|
GB9505491D0
(en)
*
|
1995-03-18 |
1995-05-03 |
Merck Sharp & Dohme |
Therapeutic agents
|
GB9523244D0
(en)
*
|
1995-11-14 |
1996-01-17 |
Merck Sharp & Dohme |
Therapeutic agents
|
US6117855A
(en)
*
|
1996-10-07 |
2000-09-12 |
Merck Sharp & Dohme Ltd. |
Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
|
US5750549A
(en)
*
|
1996-10-15 |
1998-05-12 |
Merck & Co., Inc. |
Cycloalkyl tachykinin receptor antagonists
|
US6114315A
(en)
*
|
1996-12-02 |
2000-09-05 |
Merck Sharp & Dohme Ltd. |
Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety
|
JP2001508412A
(ja)
*
|
1996-12-02 |
2001-06-26 |
メルク シヤープ エンド ドーム リミテツド |
認識障害の治療のためのnk−1受容体拮抗薬の使用
|
US6100256A
(en)
*
|
1996-12-02 |
2000-08-08 |
Merck Sharp & Dohme Ltd. |
Use of NK-1 receptors antagonists for treating schizophrenic disorders
|
US6613765B1
(en)
*
|
1996-12-02 |
2003-09-02 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating major depressive disorders
|
WO1998024443A1
(en)
*
|
1996-12-02 |
1998-06-11 |
Merck Sharp & Dohme Limited |
Use of nk-1 receptor antagonists for treating bipolar disorders
|
WO1998024442A1
(en)
*
|
1996-12-02 |
1998-06-11 |
Merck Sharp & Dohme Limited |
Use of nk-1 receptor antagonists for treating sexual dysfunction
|
EP0942732B1
(en)
*
|
1996-12-02 |
2004-11-17 |
MERCK SHARP & DOHME LTD. |
Use of nk-1 receptor antagonists for treating movement disorders
|
US5977104A
(en)
*
|
1996-12-02 |
1999-11-02 |
Merck Sharp & Dohme Ltd. |
Use of NK-1 receptor antagonists for treating bipolar disorders
|
JP2001524960A
(ja)
*
|
1997-04-24 |
2001-12-04 |
メルク シヤープ エンド ドーム リミテツド |
摂食障害を治療するためのnk−1受容体拮抗薬の使用
|
GB9716457D0
(en)
*
|
1997-08-04 |
1997-10-08 |
Merck Sharp & Dohme |
Therapeutic agents
|
CA2298777A1
(en)
*
|
1997-08-04 |
1999-02-18 |
Merck Sharp & Dohme Limited |
Use of nk-1 receptor antagonists for treating mania
|
WO1999007375A1
(en)
*
|
1997-08-04 |
1999-02-18 |
Merck Sharp & Dohme Limited |
Use of nk-1 receptor antagonists for treating aggressive behaviour disorders
|
GB9716463D0
(en)
*
|
1997-08-04 |
1997-10-08 |
Merck Sharp & Dohme |
Therapeutic agents
|
US6087348A
(en)
*
|
1997-12-01 |
2000-07-11 |
Merck Sharp & Dohme Ltd. |
Use of NK-1 receptor antagonists for treating stress disorders
|
GB9813025D0
(en)
*
|
1998-06-16 |
1998-08-12 |
Merck Sharp & Dohme |
Chemical synthesis
|
GB9816897D0
(en)
*
|
1998-08-04 |
1998-09-30 |
Merck Sharp & Dohme |
Therapeutic use
|
EP1035115B1
(en)
|
1999-02-24 |
2004-09-29 |
F. Hoffmann-La Roche Ag |
4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
|
WO2000050398A2
(en)
|
1999-02-24 |
2000-08-31 |
F. Hoffmann-La Roche Ag |
Phenyl- and pyridinyl derivatives as neurokinin 1 antagonists
|
AU772446B2
(en)
|
1999-02-24 |
2004-04-29 |
F. Hoffmann-La Roche Ag |
3-phenylpyridine derivatives and their use as NK-1 receptor antagonists
|
US6291465B1
(en)
|
1999-03-09 |
2001-09-18 |
Hoffmann-La Roche Inc. |
Biphenyl derivatives
|
FR2792835B3
(fr)
*
|
1999-04-27 |
2001-05-25 |
Sanofi Sa |
Utilisation du saredutant pour la preparation de medicaments utiles dans le traitement ou la prevention de l'ensemble des troubles de l'humeur, des troubles de l'adaptation ou des troubles mixtes anxiete-depression
|
USRE39921E1
(en)
|
1999-10-07 |
2007-11-13 |
Smithkline Beecham Corporation |
Chemical compounds
|
GB9923748D0
(en)
|
1999-10-07 |
1999-12-08 |
Glaxo Group Ltd |
Chemical compounds
|
US6552025B1
(en)
*
|
1999-11-24 |
2003-04-22 |
Emory University |
Diimino-piperazine derivatives for use as modulators of cell regulation
|
PT1103545E
(pt)
*
|
1999-11-29 |
2004-03-31 |
Hoffmann La Roche |
2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-o-totil-piridin-3-il)-isobutiramida
|
US6452001B2
(en)
|
2000-05-25 |
2002-09-17 |
Hoffmann-La Roche Inc. |
Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation
|
US6482829B2
(en)
|
2000-06-08 |
2002-11-19 |
Hoffmann-La Roche Inc. |
Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor
|
KR100501608B1
(ko)
|
2000-07-14 |
2005-07-18 |
에프. 호프만-라 로슈 아게 |
4-페닐-피리딘 유도체의 nk1 수용체의 길항성선구약물로서의 n-산화물
|
TWI287003B
(en)
|
2000-07-24 |
2007-09-21 |
Hoffmann La Roche |
4-phenyl-pyridine derivatives
|
TWI259180B
(en)
|
2000-08-08 |
2006-08-01 |
Hoffmann La Roche |
4-Phenyl-pyridine derivatives
|
GB0025354D0
(en)
*
|
2000-10-17 |
2000-11-29 |
Glaxo Group Ltd |
Chemical compounds
|
YU39503A
(sh)
|
2000-11-22 |
2006-05-25 |
F. Hoffmann-La Roche Ag. |
Derivati pirimidina
|
US6642226B2
(en)
|
2001-02-06 |
2003-11-04 |
Hoffman-La Roche Inc. |
Substituted phenyl-piperidine methanone compounds
|
GB0108594D0
(en)
*
|
2001-04-05 |
2001-05-23 |
Glaxo Group Ltd |
Chemical compounds
|
US20030055026A1
(en)
|
2001-04-17 |
2003-03-20 |
Dey L.P. |
Formoterol/steroid bronchodilating compositions and methods of use thereof
|
US6667344B2
(en)
|
2001-04-17 |
2003-12-23 |
Dey, L.P. |
Bronchodilating compositions and methods
|
US6849624B2
(en)
|
2001-07-31 |
2005-02-01 |
Hoffmann-La Roche Inc. |
Aromatic and heteroaromatic substituted amides
|
US6638981B2
(en)
|
2001-08-17 |
2003-10-28 |
Epicept Corporation |
Topical compositions and methods for treating pain
|
MY130373A
(en)
*
|
2001-10-29 |
2007-06-29 |
Malesci Sas |
Linear basic compounds having nk-2 antagonist activity and formulations thereof
|
US6903129B2
(en)
*
|
2001-12-14 |
2005-06-07 |
Hoffman-La Roche Inc. |
D-proline prodrugs
|
US7482365B2
(en)
*
|
2002-02-08 |
2009-01-27 |
Glaxo Group Limited |
Piperidylcarboxamide derivatives and their use in the treatment of tachykinin-mediated diseases
|
GB0203022D0
(en)
*
|
2002-02-08 |
2002-03-27 |
Glaxo Group Ltd |
Chemical compounds
|
GB0203020D0
(en)
*
|
2002-02-08 |
2002-03-27 |
Glaxo Group Ltd |
Chemical compounds
|
AR039625A1
(es)
*
|
2002-04-18 |
2005-03-02 |
Merck & Co Inc |
Proceso para la preparacion de 5-((2(r)--(1(r)- (3,5-bis (trifluormetil) fenil)etoxi-3 (s) - (4-fluorfenil) -4-morfolinil) metil) -1,2-dihidro-3h-1,2,4-triazol-3-ona
|
US20060205724A1
(en)
*
|
2002-05-29 |
2006-09-14 |
The Regents Of The University Of California |
Antagonizing nk-1 receptors inhibits consumption of substances of abuse
|
US20040023935A1
(en)
*
|
2002-08-02 |
2004-02-05 |
Dey, L.P. |
Inhalation compositions, methods of use thereof, and process for preparation of same
|
US20040109826A1
(en)
*
|
2002-12-06 |
2004-06-10 |
Dey, L.P. |
Stabilized albuterol compositions and method of preparation thereof
|
CA2514037C
(en)
|
2003-01-31 |
2012-03-13 |
F. Hoffmann-La Roche Ag |
Crystalline modification of 2-(3,5-bis-trifluoromethyl-phenyl)-n-[6-(1,1-dioxo-1.lambda.6-thiomorpholin-4-yl)-4(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-n-methyl-isobutyramide
|
NZ544244A
(en)
|
2003-07-03 |
2008-10-31 |
Hoffmann La Roche |
Dual NK1/NK3 antagonists for treating schizophrenia
|
TWI359675B
(en)
*
|
2003-07-10 |
2012-03-11 |
Dey L P |
Bronchodilating β-agonist compositions
|
US7288658B2
(en)
|
2003-07-15 |
2007-10-30 |
Hoffmann-La Roche Inc. |
Process for preparation of pyridine derivatives
|
US7932272B2
(en)
*
|
2003-09-30 |
2011-04-26 |
Eisai R&D Management Co., Ltd. |
Antifungal agent containing heterocyclic compound
|
US20070020299A1
(en)
|
2003-12-31 |
2007-01-25 |
Pipkin James D |
Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
|
US20070020298A1
(en)
*
|
2003-12-31 |
2007-01-25 |
Pipkin James D |
Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
|
RU2390330C2
(ru)
|
2003-12-31 |
2010-05-27 |
Сайдекс, Инк. |
Ингаляционная препаративная форма, содержащая простой сульфоалкиловый эфир гамма-циклодекстрина и кортикостероид
|
ES2246687B2
(es)
|
2004-02-11 |
2006-11-16 |
Miguel Muñoz Saez |
Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales.
|
WO2005088655A1
(en)
*
|
2004-03-12 |
2005-09-22 |
The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin |
A magnetoresistive medium
|
MXPA06012240A
(es)
|
2004-04-23 |
2007-01-31 |
Cydex Inc |
Formulacion para inhalador de polvo seco que contiene eter sulfoalquilico-ciclodextrina.
|
KR101412339B1
(ko)
|
2004-07-15 |
2014-06-25 |
알바니 몰레큘라 리써치, 인크. |
아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를차단하기 위한 용도
|
JPWO2006016548A1
(ja)
*
|
2004-08-09 |
2008-05-01 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
ヘテロ環化合物を含有する新規な抗マラリア剤
|
JP2008509909A
(ja)
*
|
2004-08-11 |
2008-04-03 |
ウィリアムスバーグ・ホールディングス・エルエルシー |
心毒性のない医薬化合物
|
US7223737B1
(en)
|
2004-08-13 |
2007-05-29 |
Alcon, Inc. |
Method of treating dry eye disorders using glycosides
|
AR051475A1
(es)
*
|
2004-11-05 |
2007-01-17 |
Merck & Co Inc |
Procedimiento para acido{3- [2 (r) -[(1r) - 1-[ 3,5- bis( trifluorometil)- fenil] etoxi] -3 (s) - (4- fluorfenil) morfolin -4- il]metil -5-oxo-4,5-dihidro- [1,2,4]-triazol-1-il} fosfonico
|
ES2329827T3
(es)
|
2005-02-22 |
2009-12-01 |
F. Hoffmann-La Roche Ag |
Antagonistas de nk1.
|
CN101146775B
(zh)
|
2005-03-23 |
2012-07-18 |
弗·哈夫曼-拉罗切有限公司 |
用于呕吐的用作nk-i拮抗剂的代谢物
|
JP4874958B2
(ja)
*
|
2005-03-30 |
2012-02-15 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
ピリジン誘導体を含有する抗真菌剤
|
US8362075B2
(en)
|
2005-05-17 |
2013-01-29 |
Merck Sharp & Dohme Corp. |
Cyclohexyl sulphones for treatment of cancer
|
CN101495184A
(zh)
|
2005-07-15 |
2009-07-29 |
Amr科技公司 |
芳基和杂芳基取代的四氢苯并氮杂及其在阻断去甲肾上腺素多巴胺和血清素的重摄取中的应用
|
EP1928427B1
(en)
|
2005-09-23 |
2009-12-30 |
F.Hoffmann-La Roche Ag |
Novel dosage formulation
|
AU2006297443B2
(en)
|
2005-09-29 |
2010-08-12 |
Merck Sharp & Dohme Corp. |
Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
|
US8080656B2
(en)
*
|
2005-10-05 |
2011-12-20 |
Ranbaxy Laboratories Limited |
Process for the preparation of aprepitant
|
US7629331B2
(en)
|
2005-10-26 |
2009-12-08 |
Cydex Pharmaceuticals, Inc. |
Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
|
TWI385169B
(zh)
|
2005-10-31 |
2013-02-11 |
Eisai R&D Man Co Ltd |
經雜環取代之吡啶衍生物及含有彼之抗真菌劑
|
US20070160542A1
(en)
*
|
2005-12-20 |
2007-07-12 |
Verus Pharmaceuticals, Inc. |
Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
|
US20070185066A1
(en)
*
|
2005-12-20 |
2007-08-09 |
Verus Pharmaceuticals, Inc. |
Systems and methods for the delivery of corticosteroids
|
US20070249572A1
(en)
*
|
2005-12-20 |
2007-10-25 |
Verus Pharmaceuticals, Inc. |
Systems and methods for the delivery of corticosteroids
|
US20070178049A1
(en)
*
|
2005-12-20 |
2007-08-02 |
Verus Pharmaceuticals, Inc. |
Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
|
US20070197486A1
(en)
*
|
2005-12-20 |
2007-08-23 |
Verus Pharmaceuticals, Inc. |
Methods and systems for the delivery of corticosteroids
|
US9227958B2
(en)
*
|
2006-02-03 |
2016-01-05 |
Glenmark Pharmaceuticals Limited |
Amorphous and crystalline forms of aprepitant and processes for the preparation thereof
|
CA2642579A1
(en)
*
|
2006-02-15 |
2007-08-23 |
Tika Lakemedel Ab |
Sterilization of corticosteroids with reduced mass loss
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
US8183264B2
(en)
*
|
2006-09-21 |
2012-05-22 |
Eisai R&D Managment Co., Ltd. |
Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same
|
EP2083831B1
(en)
|
2006-09-22 |
2013-12-25 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
SI2805945T1
(sl)
|
2007-01-10 |
2019-09-30 |
Msd Italia S.R.L. |
Amid substituirani indazoli, kot inhibitorji poli(ADP-riboza)polimeraze(PARP)
|
WO2008090117A1
(en)
|
2007-01-24 |
2008-07-31 |
Glaxo Group Limited |
Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1
|
AU2008233662B2
(en)
|
2007-04-02 |
2012-08-23 |
Msd K.K. |
Indoledione derivative
|
CA2682506C
(en)
|
2007-04-20 |
2016-05-24 |
F. Hoffmann-La Roche Ag |
Pyrrolidine derivatives as dual nk1/nk3 receptor antagonists
|
TW200841879A
(en)
*
|
2007-04-27 |
2008-11-01 |
Eisai R&D Man Co Ltd |
Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same
|
CN102702185A
(zh)
*
|
2007-04-27 |
2012-10-03 |
卫材R&D管理有限公司 |
杂环取代吡啶衍生物的盐的结晶
|
EP1994930A1
(en)
*
|
2007-05-22 |
2008-11-26 |
Novartis AG |
Triazol compounds for treating biofilm formation
|
CA2690191C
(en)
|
2007-06-27 |
2015-07-28 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
CN101778837A
(zh)
|
2007-08-07 |
2010-07-14 |
弗·哈夫曼-拉罗切有限公司 |
作为nk3受体拮抗剂的吡咯烷芳基-醚
|
US20090076007A1
(en)
*
|
2007-09-17 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched aprepitant
|
US20090076008A1
(en)
*
|
2007-09-17 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched fosaprepitant
|
US8513287B2
(en)
|
2007-12-27 |
2013-08-20 |
Eisai R&D Management Co., Ltd. |
Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
|
WO2009104080A2
(en)
|
2008-02-20 |
2009-08-27 |
Targia Pharmaceuticals |
Cns pharmaceutical compositions and methods of use
|
CA2717509A1
(en)
|
2008-03-03 |
2009-09-11 |
Tiger Pharmatech |
Tyrosine kinase inhibitors
|
US20100048524A1
(en)
|
2008-03-14 |
2010-02-25 |
Angela Brodie |
Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
|
US9156812B2
(en)
|
2008-06-04 |
2015-10-13 |
Bristol-Myers Squibb Company |
Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
|
ES2550003T5
(es)
*
|
2008-07-17 |
2018-08-22 |
Glenmark Pharmaceuticals Limited |
Producto intermedio de dimeglumina de fosaprepitant, fosaprepitant neutro y dimeglumina de fosaprepitant amorfa, y procesos para sus preparaciones
|
US8188119B2
(en)
*
|
2008-10-24 |
2012-05-29 |
Eisai R&D Management Co., Ltd |
Pyridine derivatives substituted with heterocyclic ring and γ-glutamylamino group, and antifungal agents containing same
|
AU2010210422A1
(en)
|
2009-02-05 |
2011-08-18 |
Tokai Pharmaceuticals, Inc. |
Novel prodrugs of steroidal CYP17 inhibitors/antiandrogens
|
BRPI1014125A2
(pt)
|
2009-03-17 |
2016-04-12 |
Daiichi Sankyo Co Ltd |
composto, composição farmacêutica, e, uso de um composto.
|
EP2413932A4
(en)
|
2009-04-01 |
2012-09-19 |
Merck Sharp & Dohme |
INHIBITORS OF AKT ACTIVITY
|
CA2760837C
(en)
|
2009-05-12 |
2018-04-03 |
Albany Molecular Research, Inc. |
7-([1,2,4]triazolo[1,5-.alpha.]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
|
US9034899B2
(en)
|
2009-05-12 |
2015-05-19 |
Albany Molecular Research, Inc. |
Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
|
US8815894B2
(en)
|
2009-05-12 |
2014-08-26 |
Bristol-Myers Squibb Company |
Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
|
UY32799A
(es)
|
2009-07-24 |
2011-02-28 |
Novartis Ag |
Derivados de oxazina y su uso en el tratamiento de trastornos neurológicos
|
US8188079B2
(en)
*
|
2009-08-19 |
2012-05-29 |
Hoffman-La Roche Inc. |
3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines
|
CA2777043C
(en)
|
2009-10-14 |
2015-12-15 |
Schering Corporation |
Substituted piperidines that increase p53 activity and the uses thereof
|
WO2011045817A2
(en)
*
|
2009-10-15 |
2011-04-21 |
Sandoz Private Limited |
Process for the preparation of fosaprepitant, intermediate and pharmaceutical acceptable salt thereof
|
WO2011120044A1
(en)
*
|
2010-03-26 |
2011-09-29 |
Duke University |
Conjugated neuroactive steroid compositions and methods of use
|
US8487102B2
(en)
|
2010-04-20 |
2013-07-16 |
Hoffmann-La Roche Inc. |
Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists
|
US8999957B2
(en)
|
2010-06-24 |
2015-04-07 |
Merck Sharp & Dohme Corp. |
Heterocyclic compounds as ERK inhibitors
|
SG178311A1
(en)
|
2010-07-13 |
2012-03-29 |
Novartis Ag |
Oxazine derivatives and their use in the treatment of neurological disorders
|
US9446029B2
(en)
|
2010-07-27 |
2016-09-20 |
Colorado State University Research Foundation |
Use of NK-1 receptor antagonists in management of visceral pain
|
US8518907B2
(en)
|
2010-08-02 |
2013-08-27 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
|
ES2376564B1
(es)
|
2010-08-12 |
2013-01-24 |
Manuel Vicente Salinas Martín |
Utilización de anticuerpos contra los receptores nk1, nk2 y/o nk3, para producir apoptosis en las células tumorales y modificar el estroma, la inmunidad y la vascularización intra y peritumorales, como tratamiento del cáncer.
|
EP2606134B1
(en)
|
2010-08-17 |
2019-04-10 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US8883801B2
(en)
|
2010-08-23 |
2014-11-11 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
|
WO2012030685A2
(en)
|
2010-09-01 |
2012-03-08 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
WO2012036997A1
(en)
|
2010-09-16 |
2012-03-22 |
Schering Corporation |
Fused pyrazole derivatives as novel erk inhibitors
|
EP3766975A1
(en)
|
2010-10-29 |
2021-01-20 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
|
US9351965B2
(en)
|
2010-12-21 |
2016-05-31 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as ERK inhibitors
|
US8524897B2
(en)
|
2011-01-12 |
2013-09-03 |
Novartis Ag |
Crystalline oxazine derivative
|
JP5715710B2
(ja)
|
2011-01-13 |
2015-05-13 |
ノバルティス アーゲー |
新規複素環誘導体および神経障害の処置におけるそれらの使用
|
CN102127031B
(zh)
*
|
2011-01-17 |
2012-10-17 |
江苏江神药物化学有限公司 |
一种麻黄碱类化合物季胺盐及其合成方法和应用
|
US9067924B2
(en)
*
|
2011-03-04 |
2015-06-30 |
Hoffmann-La Roche Inc. |
1,4 thiazepines/sulfones as BACE1 and/or BACE2 inhibitors
|
FR2973031B1
(fr)
*
|
2011-03-23 |
2013-11-29 |
Univ Strasbourg |
Derives de l'allopregnanolone et de l'epiallopregnanolone et leurs utilisations pour traiter un etat neuropathologique
|
WO2012129673A1
(en)
*
|
2011-03-25 |
2012-10-04 |
Universite Laval |
INHIBITORS OF 17ß-HSD1, 17ß-HSD3 AND 17ß-HSD10
|
WO2012143879A1
(en)
|
2011-04-21 |
2012-10-26 |
Piramal Healthcare Limited |
A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
|
WO2012146692A1
(en)
|
2011-04-29 |
2012-11-01 |
Sandoz Ag |
Novel intermediates for the preparation of highly pure aprepitant or fosaprepitant
|
JP5952898B2
(ja)
*
|
2011-06-07 |
2016-07-13 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
[1,3]オキサジン
|
WO2013004766A1
(en)
|
2011-07-04 |
2013-01-10 |
Ferrari Giulio |
Nk-1 receptor antagonists for treating corneal neovascularisation
|
CN102977142B
(zh)
*
|
2011-09-02 |
2017-03-29 |
江苏豪森药业集团有限公司 |
福沙匹坦二甲葡胺的制备方法
|
EP2770987B1
(en)
|
2011-10-27 |
2018-04-04 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
US20150297613A1
(en)
|
2011-12-13 |
2015-10-22 |
Servicio Andaluz De Salud |
Use of agents that alter the peritumoral environment for the treatment of cancer
|
US8338413B1
(en)
|
2012-03-07 |
2012-12-25 |
Novartis Ag |
Oxazine derivatives and their use in the treatment of neurological disorders
|
WO2013168176A2
(en)
*
|
2012-03-30 |
2013-11-14 |
Glenmark Generics Limited |
Process for preparation of fosaprepitant and salt thereof
|
CZ304982B6
(cs)
*
|
2012-04-30 |
2015-03-11 |
Zentiva, K.S. |
Způsob přípravy a čištění nových polymorfů intermediátu fosaprepitantu
|
WO2013165816A2
(en)
|
2012-05-02 |
2013-11-07 |
Merck Sharp & Dohme Corp. |
SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
|
CN102675369B
(zh)
*
|
2012-05-16 |
2017-07-11 |
北京华众思康医药技术有限公司 |
一种制备[3‑[(2r)‑[(1r)‑1‑[3,5‑二(三氟甲基)苯基]乙氧基]‑3(s)‑(4‑氟苯基)吗啉‑4‑基]甲基]‑5‑氧代‑4,5‑二氢‑[1,2,4]‑三唑‑1‑基]膦酸一苄酯的新方法
|
IN2014DN10548A
(fi)
*
|
2012-05-31 |
2015-08-21 |
Repros Therapeutics Inc |
|
PT2866797T
(pt)
|
2012-07-06 |
2020-07-22 |
Pharmathen Sa |
Composição farmacêutica injetável estável do antagonista do recetor da neurocinina 1 e seu processo de preparação
|
AU2013323508B2
(en)
|
2012-09-28 |
2017-11-02 |
Merck Sharp & Dohme Corp. |
Novel compounds that are ERK inhibitors
|
WO2014070784A1
(en)
*
|
2012-10-29 |
2014-05-08 |
Allergan, Inc. |
Phosphate esters of bimatoprost and the prostamides
|
US8778964B2
(en)
|
2012-11-05 |
2014-07-15 |
Bayer Pharma Aktiengesellschaft |
Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use
|
US9624214B2
(en)
|
2012-11-05 |
2017-04-18 |
Bayer Pharma Aktiengesellschaft |
Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
|
US8796305B2
(en)
|
2012-11-05 |
2014-08-05 |
Bayer Pharma Aktiengesellschaft |
Carboxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use
|
US9126998B2
(en)
|
2012-11-05 |
2015-09-08 |
Bayer Pharma AG |
Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
|
ES2651347T3
(es)
|
2012-11-28 |
2018-01-25 |
Merck Sharp & Dohme Corp. |
Composiciones y métodos para el tratamiento del cáncer
|
CA2895504A1
(en)
|
2012-12-20 |
2014-06-26 |
Merck Sharp & Dohme Corp. |
Substituted imidazopyridines as hdm2 inhibitors
|
US9540377B2
(en)
|
2013-01-30 |
2017-01-10 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as HDM2 inhibitors
|
ES2493693B1
(es)
|
2013-02-11 |
2015-07-07 |
Servicio Andaluz De Salud |
Método para predecir o pronosticar la respuesta de un sujeto humano que padece un cáncer al tratamiento con un antagonista del receptor NK1
|
US20160009755A1
(en)
*
|
2013-03-01 |
2016-01-14 |
Revlon Consumer Products Corporation |
Cyrrhetinic alkyl esters and protected derivatives thereof
|
SI3461834T1
(sl)
|
2013-03-13 |
2021-11-30 |
Sage Therapeutics, Inc. |
Nevroaktivni steroidi
|
EP4066841A1
(en)
|
2013-03-14 |
2022-10-05 |
University of Maryland, Baltimore |
Androgen receptor down-regulating agents and uses thereof
|
US20160060288A1
(en)
*
|
2013-04-18 |
2016-03-03 |
Xi'anlibang Pharmaceutical Technology Co., Ltd. |
Ester derivatives of 7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-estra-1,3,5(10)-triene-3,17beta-diol having anticancer activity and preparation method thereof
|
CA2914100A1
(en)
|
2013-06-04 |
2014-12-11 |
Bayer Pharma Aktiengesellschaft |
3-aryl-substituted imidazo[1,2-a]pyridines and the use thereof
|
SG11201600525XA
(en)
|
2013-08-12 |
2016-02-26 |
Tokai Pharmaceuticals Inc |
Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
|
US20160194368A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
JP6548641B2
(ja)
|
2013-10-28 |
2019-07-24 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
転移性前立腺癌の治療
|
CN104650142B
(zh)
*
|
2013-11-25 |
2018-06-22 |
山东新时代药业有限公司 |
一种福沙匹坦二甲葡胺的制备方法
|
CN103694146B
(zh)
*
|
2013-12-04 |
2015-10-28 |
深圳万乐药业有限公司 |
2-(2-氯-1-亚乙基)酰肼甲酸甲酯的制备方法
|
ES2541870B1
(es)
|
2013-12-27 |
2016-05-12 |
Servicio Andaluz De Salud |
Uso de antagonistas no peptídicos de NK1 en una determinada dosis para el tratamiento del cáncer
|
WO2015101596A2
(en)
|
2013-12-30 |
2015-07-09 |
Oncoprevent Gmbh |
Neurokinin-1 receptor antagonists for use in a method of prevention of cancer
|
CA2939793A1
(en)
|
2014-02-19 |
2015-08-27 |
Bayer Pharma Aktiengesellschaft |
3-(pyrimidine-2-yl)imidazo[1,2-a]pyridines
|
US9771360B2
(en)
|
2014-03-21 |
2017-09-26 |
Bayer Pharma Aktiengesellschaft |
Cyano-substituted imidazo[1,2-A]pyridinecarboxamides and their use
|
TW201613888A
(en)
|
2014-09-26 |
2016-04-16 |
Helsinn Healthcare Sa |
Crystalline forms of an NK-1 antagonist
|
CA2969268A1
(en)
|
2014-12-02 |
2016-06-09 |
Bayer Pharma Aktiengesellschaft |
Heteroaryl-substituted imidazo[1,2-a]pyridines and their use
|
PE20180482A1
(es)
|
2015-07-06 |
2018-03-07 |
Sage Therapeutics Inc |
Oxiesteroles y metodos de uso de los mismos
|
US10610532B2
(en)
|
2015-08-03 |
2020-04-07 |
Leiutis Pharmaceuticals Pvt. Ltd. |
Liquid formulations of fosaprepitant
|
US10005803B2
(en)
|
2015-10-06 |
2018-06-26 |
Helsinn Healthcare Sa |
Crystalline forms of fosnetupitant
|
US9913853B2
(en)
|
2015-11-03 |
2018-03-13 |
Cipla Limited |
Stabilized liquid fosaprepitant formulations
|
US10428097B2
(en)
|
2015-12-01 |
2019-10-01 |
Piramal Enterprises Limited |
Process for preparation of fosaprepitant dimeglumine and an intermediate thereof
|
CN105837526B
(zh)
*
|
2016-01-22 |
2018-02-27 |
浙江工业大学 |
一种阿瑞吡坦重要合成中间体(2s,3r)‑4‑苄基‑3‑(4‑氟苯基)吗啉‑2‑醇的制备方法
|
AU2017240157B2
(en)
|
2016-04-01 |
2022-10-20 |
Sage Therapeutics, Inc. |
Oxysterols and methods of use thereof
|
US10752653B2
(en)
|
2016-05-06 |
2020-08-25 |
Sage Therapeutics, Inc. |
Oxysterols and methods of use thereof
|
CN107353303B
(zh)
|
2016-05-09 |
2020-09-01 |
上海奥博生物医药技术有限公司 |
一种福沙匹坦磷酸酯中间体的制备方法
|
LT3435980T
(lt)
|
2016-06-06 |
2020-02-25 |
Helsinn Healthcare Sa |
Fiziologiškai subalansuotos injekcinės fosnetupitanto kompozicijos
|
DK3481846T3
(da)
|
2016-07-07 |
2021-08-16 |
Sage Therapeutics Inc |
11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
|
JP7149266B2
(ja)
|
2016-09-30 |
2022-10-06 |
セージ セラピューティクス, インコーポレイテッド |
C7置換オキシステロールおよびnmdaモジュレーターとしての方法
|
EP3525785A4
(en)
|
2016-10-12 |
2020-03-25 |
Merck Sharp & Dohme Corp. |
KDM5 INHIBITORS
|
WO2018075698A1
(en)
|
2016-10-18 |
2018-04-26 |
Sage Therapeutics, Inc. |
Oxysterols and methods of use thereof
|
EP3529257B1
(en)
|
2016-10-18 |
2023-05-10 |
Sage Therapeutics, Inc. |
Oxysterols and methods of use thereof
|
CN110730662A
(zh)
|
2017-04-10 |
2020-01-24 |
才思治疗公司 |
用于治疗共核蛋白病的nk1-拮抗剂组合和方法
|
US11266633B2
(en)
|
2017-06-30 |
2022-03-08 |
Chase Therapeutics Corporation |
NK-1 antagonist compositions and methods for use in treating depression
|
EP3672964A4
(en)
|
2017-08-21 |
2021-05-26 |
Leiutis Pharmaceuticals Pvt. Ltd. |
NEW TRIPLE COMBINATION FORMULATIONS FOR ANTIEMETIC THERAPY
|
CN109694390A
(zh)
*
|
2017-10-24 |
2019-04-30 |
齐鲁制药有限公司 |
一种福沙匹坦氮氧化物
|
WO2019094311A1
(en)
|
2017-11-08 |
2019-05-16 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
EP4371613A3
(en)
|
2018-02-26 |
2024-07-24 |
Ospedale San Raffaele S.r.l. |
Compounds for use in the treatment of ocular pain
|
WO2020033282A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
EP3833667B1
(en)
|
2018-08-07 |
2024-03-13 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|
WO2021180885A1
(en)
|
2020-03-11 |
2021-09-16 |
Ospedale San Raffaele S.R.L. |
Treatment of stem cell deficiency
|
CA3173697A1
(en)
|
2020-04-03 |
2021-10-07 |
Mike TROWER |
An nk-1 receptor antagonist for treating a disease selecting from sepsis, septic shock, acute respiratory distress syndrome (ards) or multiple organ dysfunction syndrome (mods)
|
BR112022024208A2
(pt)
|
2020-06-02 |
2022-12-20 |
Nerre Therapeutics Ltd |
Antagonistas do receptor de neurocinina (nk)-1 para uso no tratamento de condições de fibrose pulmonar promovidas por lesão mecânica aos pulmões
|
WO2022107843A1
(ja)
|
2020-11-19 |
2022-05-27 |
日本化薬株式会社 |
血管障害を発症する水溶性薬含有組成物、血管障害を発症する水溶性薬含有投与液調製用溶液、キット、血管障害抑制剤、及びノニオン型界面活性剤含有溶液
|
EP4052696A1
(en)
|
2021-03-04 |
2022-09-07 |
Extrovis AG |
Stable ready-to-use parenteral compositions of fosaprepitant
|
CN113582982B
(zh)
*
|
2021-06-15 |
2023-06-16 |
山东罗欣药业集团股份有限公司 |
一种nk1受体拮抗剂的制备方法
|